By Daily Touch Insights Editorial Team
Editorial Team
View Journalist Profile
BUSINESS & FOOD TECHNOLOGY — Nestlé is developing new food and nutrition products designed to meet the changing needs of people using popular weight-loss medicines, as the rapid growth of GLP-1 drugs begins to reshape how consumers eat and how food companies develop products.
The world's largest food company sees the rise of medicines such as Ozempic, Wegovy, Mounjaro and Zepbound not only as a challenge to traditional food consumption but also as a new opportunity for product innovation.
GLP-1 medicines reduce appetite and can lead people to eat smaller portions and fewer snacks. Nestlé is responding by exploring products with higher levels of protein and fibre, smaller portions and nutritional profiles designed around the needs of people eating less food.
GLP-1 Drugs Are Changing Eating Habits
Weight-loss medicines known as GLP-1 receptor agonists have rapidly changed the obesity-treatment market.
These medicines can reduce appetite, slow digestion and increase feelings of fullness. As a result, many users consume less food than they did before starting treatment.
That change has created a new challenge for food manufacturers.
Companies that traditionally depend on frequent snacking and large portions must now compete for consumers who may be less interested in food and more focused on nutritional value.
Nestlé Sees an Opportunity in the Change
Rather than treating GLP-1 medicines purely as a threat to its food business, Nestlé is attempting to develop products specifically suited to the new eating patterns.
The company has already introduced products aimed at people using weight-management medicines, including its Vital Pursuit range.
Nestlé is also working on broader nutrition products that can provide protein, fibre, vitamins and minerals in smaller amounts of food.
The strategy reflects a major shift in the food industry: selling more nutrition in smaller portions rather than simply encouraging consumers to eat more.
Protein Has Become a Major Focus
One of Nestlé's major priorities is protein.
People who consume substantially less food may find it more difficult to obtain enough protein from their normal diet.
Nestlé's scientists are therefore exploring products designed to provide meaningful amounts of protein without requiring consumers to eat large portions.
The company's Boost Advanced Nutrition Shake is one example of a product that combines protein with prebiotic fibre, vitamins and minerals.
Nestlé says its nutrition research is focused partly on helping people maintain muscle mass while losing weight.
Muscle Loss Is Becoming an Important Concern
Weight loss is not simply about reducing the number on a scale.
Rapid weight loss can involve the loss of lean muscle as well as body fat, making muscle preservation an important issue for people undergoing weight-management treatment.
Nestlé Health Science is therefore studying how nutrition can support muscle health during weight loss.
The company says protein quality and adequate nutrition are becoming increasingly important as people consume fewer calories.
Fibre Is Another Priority
Fibre is another major area of focus for Nestlé.
Because GLP-1 medicines can reduce the amount of food a person consumes, users may also consume less fibre overall.
Nestlé is therefore exploring ways to provide more fibre and support digestive health in smaller portions.
The company's research also highlights the importance of gut health as part of long-term weight management.
Nestlé Is Also Studying Taste
The changes caused by GLP-1 medicines may extend beyond appetite.
Recent research and consumer testing have prompted Nestlé to investigate whether some users experience changes in how they perceive flavours.
The company has been working with consumers using GLP-1 medicines to understand how their food preferences change.
Possible product adjustments include stronger flavours and greater use of spices to make smaller portions more appealing.
Smaller Portions Could Become More Important
The traditional food industry has often competed by offering larger portions and encouraging consumers to buy more.
GLP-1 medicines challenge that model.
If consumers consistently eat less, companies may need to rethink portion sizes and packaging.
Nestlé has already been developing products designed around smaller portions and higher nutritional density.
This could become a broader trend across the packaged-food industry.
Nestlé Is Using AI in Product Development
The company's response is also increasingly connected to artificial intelligence.
Nestlé scientists are using AI tools to analyse nutritional information, examine recipes and identify combinations of ingredients that could meet specific consumer needs.
The company's Food Genie platform can analyse a large database of recipes and help researchers explore possible reformulations.
Nestlé is also using digital tools to monitor consumer discussions and identify changing food preferences.
The goal is to reduce the time required to develop products that consumers are likely to want.
The Food Industry Faces a New Consumer
The rise of GLP-1 medicines could create a fundamentally different type of food consumer.
Instead of looking for maximum calories and large quantities, consumers may increasingly prioritise protein, fibre, vitamins, minerals and satisfying flavours in smaller portions.
This could force food companies to reconsider how they design everything from frozen meals to snacks and drinks.
Nestlé's strategy suggests that the company believes this change could last well beyond the current wave of interest in weight-loss medicines.
Nestlé Is Not Abandoning Traditional Food
It would be misleading to suggest that Nestlé is abandoning its existing food business.
The company continues to sell a huge range of conventional food and beverage products.
Instead, it is attempting to adapt parts of its portfolio to changing consumer behaviour.
That means developing specialised products while also reformulating mainstream products to provide more protein, fibre and nutritional value.
Experts Question Whether Special Products Are Necessary
The growing market for GLP-1-focused foods has also attracted criticism.
Some nutrition experts argue that people taking weight-loss medicines can obtain many of the nutrients they need through ordinary whole foods.
They caution that consumers should not assume that a product is automatically healthier simply because it is marketed toward people using GLP-1 medicines.
The nutritional quality of individual products still depends on their ingredients, portion sizes and overall dietary context.
Marketing Could Become a Major Battle
Food companies must also decide how openly they should market products to people taking weight-loss medicines.
Some consumers may appreciate products specifically designed for their needs.
Others may not want their medication use highlighted on food packaging.
Nestlé has therefore explored ways of making products nutritionally suitable without necessarily putting GLP-1 drug names prominently on the package.
This allows the same products to appeal to a broader audience.
Traditional Snacking Faces Pressure
Snacks could be one of the categories most affected by the rise of appetite-suppressing medicines.
People using GLP-1 drugs often report eating fewer snacks and experiencing less interest in highly indulgent foods.
For companies that depend heavily on snacks, this could become a serious long-term business challenge.
Nestlé is responding by exploring smaller treats, more nutrient-dense options and products that can deliver greater nutritional value in smaller quantities.
The Opportunity Could Be Much Bigger Than Weight Loss
Nestlé's strategy is not limited to people taking weight-loss medicines.
Products high in protein, fibre and essential nutrients can also appeal to consumers who are not using GLP-1 drugs.
This gives the company an opportunity to create products for the wider health and wellness market rather than building an entirely separate food category.
That could make the strategy commercially more sustainable.
GLP-1 Drugs Could Reshape Food Companies
The impact of weight-loss medicines could extend far beyond Nestlé.
If millions of people permanently change how much they eat, food manufacturers will have to reconsider product development, pricing, packaging and marketing.
Companies may increasingly compete on nutritional density rather than portion size.
That would represent a major change for an industry that has historically benefited from increasing food consumption.
Nestlé's Challenge Is Turning Science Into Products
Nestlé has significant scientific and research resources, but having nutritional research does not guarantee commercial success.
Consumers still care about taste, convenience and price.
A product can have an impressive nutritional profile and still fail if consumers do not enjoy eating it or cannot justify its price.
Nestlé therefore has to solve two problems simultaneously: creating nutritionally useful products and making them attractive enough to become repeat purchases.
The Bigger Business Question
The rise of GLP-1 medicines presents an unusual situation for food companies.
A pharmaceutical product is reducing the amount of food some consumers want to eat, potentially threatening established food categories.
But the same change creates demand for a new generation of nutritional products.
Nestlé's strategy is essentially an attempt to move from selling more food to selling better-targeted food.
Our Perspective
Nestlé's response to GLP-1 medicines is strategically interesting because the company is not simply trying to protect its existing products.
It is adapting to the possibility that consumer behaviour itself is changing.
The biggest opportunity may not be creating products labelled specifically for people using weight-loss drugs. It may be developing foods that are naturally higher in protein, fibre and essential nutrients while requiring smaller portions.
If GLP-1 medicines permanently change how people eat, the winners in the food industry may be the companies that learn how to deliver more nutritional value with less food.
Conclusion
Nestlé is developing and reformulating products as the rapid growth of GLP-1 weight-loss medicines changes consumer eating habits.
The company's strategy includes higher-protein and fibre-rich products, smaller portions, nutritional drinks and research into how GLP-1 users experience taste and appetite.
Nestlé is also using artificial intelligence and nutritional science to accelerate product development and understand changing consumer preferences.
However, the company faces competition from whole foods and other nutrition brands, while consumers will ultimately decide whether specialised products provide enough value to justify their prices.
The rise of weight-loss medicines is forcing the food industry to rethink a basic business assumption: when consumers eat less, companies may have to compete by making every bite count for more.
